# Biotech Innovation

China’s Weight-Loss Challenger: Hansoh Pharma’s Olapepeptide Aims for Efficacy Without the Nausea

Hansoh Pharma's Olapepeptide has moved toward commercialization in China with an accepted NDA and strong Phase III data showing 19.3% weight loss. The drug distinguishes itself through a unique biased-signaling mechanism that significantly reduces the gastrointestinal side effects common in other GLP-1 treatments.